ישראל - עברית - Ministry of Health

novartis israel ltd - zoledronic acid - תמיסה לאינפוזיה - zoledronic acid 5 mg / 100 ml - zoledronic acid - zoledronic acid - treatment of paget's disease of the bone. treatment of osteoporosis : - in post-menopausal women - in men at increased risk of fracture including those with a recent low-trauma hip fracture.treatment and prevention of glucocorticoid-induced osteoporosis.prevention of postmenopausal osteoporosis in women for whom bisphosphonate therapy is indicated.

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - risedronic acid as sodium - טבליות מצופות פילם - risedronic acid as sodium 150 mg - risedronic acid - risedronic acid - treatment of postmenopausal osteoporosis.prevention of postmenopausal osteoporosis.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - alendronic acid as sodium - טבליה - alendronic acid as sodium 70 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures).treatment to increase bone mass in men with osteoporosis.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - alendronic acid as sodium - טבליה - alendronic acid as sodium 70 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures).treatment to increase bone mass in men with osteoporosis.

ישראל - עברית - Ministry of Health

novartis israel ltd - zoledronic acid - תמיסה לאינפוזיה - zoledronic acid 5 mg / 100 ml - zoledronic acid

ישראל - עברית - Ministry of Health

unipharm ltd, israel - alendronic acid as sodium - טבליה - alendronic acid as sodium 10 mg - alendronic acid - alendronic acid - treatment of osteoporosis in postmenopausal women: maxibone is indicated for the treatment of osteoporosis to prevent fractures, including those of the hip, wrist and spine ( vertebral compression fractures). prevention and treatment of glucocorticoid-induced osteoporosis: maxibone is indicated for the prevention and treatment of glucocorticoid-induced osteoporosis in men and women. for the treatment of osteoporosis in men.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - alendronic acid as monohydrate - טבליה - alendronic acid as monohydrate 10 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip, wrist and spine (vertebral compression fractures).for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women. for the treatment to increase bone mass in men with osteoporosis.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - alendronic acid as monohydrate - טבליה - alendronic acid as monohydrate 10 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip, wrist and spine (vertebral compression fractures).for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women. for the treatment to increase bone mass in men with osteoporosis.

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - risedronic acid as sodium - טבליה - risedronic acid as sodium 35 mg - risedronic acid - risedronic acid - treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. treatment of osteoporosis in men at high risk of fracture.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - risedronic acid - טבליה - risedronic acid 35 mg - risedronic acid - risedronic acid - treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. treatment of osteoporosis in men at high risk of fracture.